Abstract: Disclosed herein are several embodiments of a negative pressure system and methods of using the same in the treatment of wounds. Some embodiments are directed to a system that utilizes a wound dressing with at least three layers. These embodiments are directed toward improved distribution of negative pressure to a wound and periwound site surrounding the wound.

Abstract: A system, and method perform compliance checking of computer records for MLS services. The compliance checking includes detecting multiple-listing-service (MLS) contract compliance with a MLS, gathering MLS-related data regarding an MLS subscriber from at least one database, checking for a non-compliance incident of the MLS-related data with the MLS service requirements, and in response to detection of a non-compliance incident, trigger a computer-based resolution process to resolve the non-compliance incident.

Abstract: A system, and method perform compliance checking of computer records for MLS services. The compliance checking includes detecting multiple-listing-service (MLS) contract compliance with a MLS, gathering MLS-related data regarding an MLS subscriber from at least one database, training an AI engine with input data containing as features MLS service requirements that correspond to contractual obligations of the MLS subscriber under a MLS license, applying the MLS-related data to the AI engine, after the AI engine is trained, and checking for a non-compliance incident of the MLS-related data with the MLS service requirements, and in response to detection of a non-compliance incident, trigger a computer-based resolution process to resolve the non-compliance incident.

Abstract: The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia.

Abstract: The invention provides certain 3,4-dihydroisoquinolin-2(1H)-yl compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat cognitive impairment associated with Parkinson's disease or schizophrenia.

Abstract: The present invention provides novel mGlu2/3 agonists of the formula wherein R1, R2, and R3 are as defined herein, for use in the treatment of neurological or psychiatric disorders.

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for the inhibition of the uptake of one or more physiologically active monoamines (serotonin, norepinephrine, and dopamine).

Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful for the inhibition of the uptake of one or more physiologically active monoamines (serotonin, norepinephrine, and dopamine).